Hepatitis Delta Virus Clade 8 Is the Predominant Clade Circulating in Botswana amongst People Living with HIV.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
04 Oct 2024
Historique:
received: 27 08 2024
revised: 27 09 2024
accepted: 01 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

Hepatitis delta virus (HDV) co-infections more often result in severe hepatitis compared to hepatitis B virus (HBV) infections alone. Despite a high HDV prevalence (7.1%), information regarding circulating HDV clades is very limited in Botswana. We extracted total nucleic acid from confirmed HDV-positive samples and quantified their viral load. We then sequenced the large hepatitis delta antigen (L-HDAg) using Oxford Nanopore Technology (ONT). Genotyping was performed using the HDV Database, and HDV mutation profiling was performed on AliView. All participants with HBV genotypic information belonged to sub-genotype A1, and 80% (4/5) of them had a higher HDV viral load and a lower HBV viral load. We sequenced 75% (9/12) of the HDV-positive samples, which belonged to HDV clade 8. A total of 54 mutations were discovered, with the most prevalent being Q148R (16%), D149P (16%) and G151D (16%). Known mutations such as S117A, K131R, R139K and G151D were detected, while the other mutations were novel. Our results reveal that HDV clade 8 is the predominant clade in Botswana. The significance of all mutations remains unclear. Future studies with a larger sample size to detect other HDV clades that might be circulating in Botswana and functionally characterize the detected mutations are warranted.

Identifiants

pubmed: 39459902
pii: v16101568
doi: 10.3390/v16101568
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
ID : 218770/Z/19/Z
Pays : United Kingdom

Auteurs

Kabo Baruti (K)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana.

Wonderful T Choga (WT)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana.

Patience C Motshosi (PC)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana.

Bonolo B Phinius (BB)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana.

Basetsana Phakedi (B)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag 00704, Botswana.

Lynnette N Bhebhe (LN)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.

Gorata G A Mpebe (GGA)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.

Chanana D Tsayang (CD)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.

Tsholofelo Ratsoma (T)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana.

Tendani Gaolathe (T)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Faculty of Medicine, University of Botswana, Gaborone Private Bag UB 0022, Botswana.

Mosepele Mosepele (M)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Faculty of Medicine, University of Botswana, Gaborone Private Bag UB 0022, Botswana.

Joseph Makhema (J)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Roger Shapiro (R)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Shahin Lockman (S)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Sikhulile Moyo (S)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Department of Pathology, Division of Medical Virology, Stellenbosch University, Cape Town 7535, South Africa.
School of Health Systems and Public Health, University of Pretoria, Pretoria 0002, South Africa.

Mosimanegape Jongman (M)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone Private Bag 00704, Botswana.

Motswedi Anderson (M)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Africa Health Research Institute (AHRI), Durban 4013, South Africa.
The Francis Crick Institute, London NW1 2BE, UK.

Simani Gaseitsiwe (S)

Research Laboratory, Botswana Harvard Health Partnership, Gaborone Private Bag BO 320, Botswana.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH